Incyte | INCY - Trade Debtors


Incyte reported $1.05B in Trade Debtors for its fiscal quarter ending in March of 2026.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 148.38M 153K Mar/2026
Agenus USD 22.44M 1.14M Dec/2025
Agios Pharmaceuticals USD 16.13M 5.56M Mar/2026
Alnylam Pharmaceuticals USD 883.96M 106.39M Mar/2026
Amgen USD 9.14B 432M Mar/2026
BioCryst Pharmaceuticals USD 106.82M 15.49M Dec/2025
Biogen USD 1.79B 76.6M Mar/2026
BioMarin Pharmaceutical USD 903.91M 4.3M Mar/2026
Bristol-Myers Squibb USD 14.36B 164M Mar/2026
Eli Lilly USD 21.18B 1.02B Mar/2026
Exelixis USD 328.95M 42.03M Mar/2026
Gilead Sciences USD 4.74B 172M Mar/2026
Incyte USD 1.05B 27.09M Mar/2026
Ionis Pharmaceuticals USD 74M 8M Mar/2026
MacroGenics USD 13.37M 55.86M Dec/2025
Merck USD 11.78B 345M Dec/2025
Moderna USD 71M 113M Mar/2026
Nektar Therapeutics USD 1.78M 1.12M Dec/2025
Neurocrine Biosciences USD 768.1M 81.3M Mar/2026
Novartis USD 9.6B 2.69B Mar/2026
Novartis USD 12.29B 3.3B Dec/2025
Pfizer USD 16.17B 332M Mar/2026
PTC Therapeutics USD 181.62M 21.45M Dec/2025
Puma Biotechnology USD 28.1M 3.52M Jun/2024
Regeneron Pharmaceuticals USD 5.73B 10.1M Mar/2026
Sarepta Therapeutics USD 547.91M 149.68M Mar/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Vertex Pharmaceuticals USD 2B 56.7M Mar/2026